(Q42228903)

19 October 2017

title

Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B. (English)

1 reference

19 October 2017

Haiqing Wu

1

1 reference

19 October 2017

Gangde Zhao

2

1 reference

19 October 2017

Fangxing Qian

3

1 reference

19 October 2017

Kehui Liu

4

1 reference

19 October 2017

Jingdong Xie

5

1 reference

19 October 2017

Huijuan Zhou

6

1 reference

19 October 2017

Jie Xu

7

1 reference

19 October 2017

Yumin Xu

8

1 reference

19 October 2017

Yan Han

9

1 reference

19 October 2017

Qing Xie

10

1 reference

19 October 2017

Hui Wang

11

1 reference

19 October 2017

language of work or name

1 reference

13 March 2014

1 reference

19 October 2017

1 reference

19 October 2017

volume

35

1 reference

19 October 2017

issue

2

1 reference

19 October 2017

page(s)

473-481

1 reference

Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference

19 October 2017

cites work

1 reference

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

21 January 2018

1 reference

Surrogate end points and long-term outcome in patients with chronic hepatitis B.

21 January 2018

1 reference

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 January 2018

1 reference

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

The treatment of chronic viral hepatitis

21 January 2018

1 reference

Relationship of human leukocyte antigen class II genes with the susceptibility to hepatitis B virus infection and the response to interferon in HBV-infected patients

21 January 2018

1 reference

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

21 January 2018

1 reference

IFN-lambda: novel antiviral cytokines

21 January 2018

1 reference

Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies

21 January 2018

1 reference

Haploview: analysis and visualization of LD and haplotype maps

21 January 2018

1 reference

The structure of haplotype blocks in the human genome

21 January 2018

1 reference

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

21 January 2018

1 reference

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.

21 January 2018

1 reference

IL28B and the control of hepatitis C virus infection

21 January 2018

1 reference

Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response

21 January 2018

1 reference

IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.

21 January 2018

1 reference

Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir.

21 January 2018

1 reference

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.

21 January 2018

1 reference

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.

21 January 2018

1 reference

Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population

21 January 2018

1 reference

Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence

21 January 2018

1 reference

IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection

21 January 2018

1 reference

IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection

21 January 2018

1 reference

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

21 January 2018

1 reference

Lambda interferon inhibits hepatitis B and C virus replication

21 January 2018

1 reference

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

Hepatitis C pharmacogenetics: state of the art in 2010.

21 January 2018

1 reference

The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain

21 January 2018

1 reference

IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

21 January 2018

1 reference

Interferon lambda as a potential new therapeutic for hepatitis C.

21 January 2018

1 reference

IL-28 and IL-29: newcomers to the interferon family

21 January 2018

1 reference

Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12491

1 reference

19 October 2017

1 reference